Popular Trials
Cyclin-Dependent Kinase Inhibitor
NKT2152 + Palbociclib + Sasanlimab for Kidney Cancer
Recruiting1 awardPhase 2
Omaha, Nebraska
This trial is testing a new drug combination for patients with advanced kidney cancer who have already tried other treatments. The goal is to see if these drugs can work better together to stop cancer growth and help the immune system fight the disease.
Popular Filters
Trials for Clear Cell Carcinoma Patients
Taxane
Combination Therapy for Pancreatic Cancer
Recruiting1 awardPhase 2
New York, New York
This trial tests a combination of standard chemotherapy, an immune-boosting drug, and a new drug to treat aggressive pancreatic cancer. The goal is to see if this mix can shrink tumors and help patients live longer. The treatment aims to kill cancer cells directly and enhance the body's immune response against the cancer. Gemcitabine is currently the standard treatment for advanced pancreatic cancer.
Anti-microtubule agent
Immunotherapy + Anti-angiogenesis + Chemotherapy for Gastroesophageal Cancer
Recruiting1 awardPhase 2
Rochester, Minnesota
This trial uses a combination of drugs to treat cancer patients who may not respond to standard treatments. The drugs help the immune system fight cancer, block blood supply to tumors, and stop cancer cells from dividing.
Trials for Pancreatic Carcinoma Patients
Taxane
Combination Therapy for Pancreatic Cancer
Recruiting1 awardPhase 2
New York, New York
This trial tests a combination of standard chemotherapy, an immune-boosting drug, and a new drug to treat aggressive pancreatic cancer. The goal is to see if this mix can shrink tumors and help patients live longer. The treatment aims to kill cancer cells directly and enhance the body's immune response against the cancer. Gemcitabine is currently the standard treatment for advanced pancreatic cancer.
Anti-microtubule agent
Immunotherapy + Anti-angiogenesis + Chemotherapy for Gastroesophageal Cancer
Recruiting1 awardPhase 2
Rochester, Minnesota
This trial uses a combination of drugs to treat cancer patients who may not respond to standard treatments. The drugs help the immune system fight cancer, block blood supply to tumors, and stop cancer cells from dividing.
Phase 3 Trials
Anti-metabolites
Chemotherapy for Pancreatic Cancer
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial is studying gemcitabine hydrochloride given with or without erlotinib hydrochloride, followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil, to see how well it works in treating patients with pancreatic cancer that has been removed by surgery.
Alkylating agents
Chemotherapy +/− Bevacizumab for Ovarian Cancer
Recruiting2 awardsPhase 3
Anchorage, Alaska
This trial is studying carboplatin, paclitaxel, and gemcitabine hydrochloride given together with or without bevacizumab after surgery to treat patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer.
Alkylating agents
Glufosfamide vs Fluorouracil for Pancreatic Cancer
Recruiting3 awardsPhase 3
Corona, California
This trial is testing if the chemotherapy drug glufosfamide can help people with advanced pancreatic cancer live longer. These patients have already tried another treatment called gemcitabine, which didn't work for them. Glufosfamide aims to stop cancer cells from growing by damaging their DNA.
Trials With No Placebo
Taxane
Combination Therapy for Pancreatic Cancer
Recruiting1 awardPhase 2
New York, New York
This trial tests a combination of standard chemotherapy, an immune-boosting drug, and a new drug to treat aggressive pancreatic cancer. The goal is to see if this mix can shrink tumors and help patients live longer. The treatment aims to kill cancer cells directly and enhance the body's immune response against the cancer. Gemcitabine is currently the standard treatment for advanced pancreatic cancer.
Anti-microtubule agent
Immunotherapy + Anti-angiogenesis + Chemotherapy for Gastroesophageal Cancer
Recruiting1 awardPhase 2
Rochester, Minnesota
This trial uses a combination of drugs to treat cancer patients who may not respond to standard treatments. The drugs help the immune system fight cancer, block blood supply to tumors, and stop cancer cells from dividing.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.